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Clinical characteristics and predictors of
gangrene in patients with systemic sclerosis
and digital ulcers in the Digital Ulcer Outcome
Registry: a prospective, observational cohort
Digital vasculopathy in systemic sclerosis (SSc) consists of a spec-
trum of Raynaud’s phenomenon (RP), digital ulcers (DUs), critical
digital ischaemia and escalation to gangrene. The complications of
severe digital vasculopathy often require hospital-based manage-
ment with intravenous therapies and surgery.1–3 Although gan-
grene is not infrequent in the clinic, data on the prevalence and
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implications of gangrene in patients with SSc are scarce.3–7 The
DU Outcomes (DUO) Registry is a European, prospective, multi-
centre, observational cohort of patients with SSc and past and/or
current DUs at enrolment.8–10 The aims of the current study were
(i) to describe the characteristics of an SSc–DU population accord-
ing to the presence/history of gangrene and (ii) to identify the risk
factors for the development of incident gangrene.
All patients in the participating centres with SSc and a history
or presence of DUs are eligible for inclusion in the DUO
Registry, irrespective of their treatment regimen. At enrolment,
data were collected on demographic and clinical variables.
Patients were categorised into three groups according to their
past history of gangrene and current gangrene status at enrol-
ment: ‘never gangrene’: no past and no current gangrene; ‘ever
gangrene’: past and/or current gangrene; and ‘current gangrene’:
gangrene reported at enrolment, irrespective of gangrene history
(a subset of the ‘ever gangrene’ group).
Categorical variables were analysed using descriptive statistics.
Potential risk factors for the development of incident gangrene
in patients with ≥1 follow-up visit and no current gangrene at
enrolment were analysed using univariable logistic regression
(ULR) conducted on demographics, clinical variables and auto-
antibody measurements collected at enrolment. Multivariable
logistic regression (MLR) using forward selection was conducted
on patients with complete covariate information using those
variables with a p value <0.15 and sample size >3000 from the
ULR models, considering interdependency among similar
factors.
Among the 4944 patients enrolled in the DUO Registry from
April 2008 to November 2014, 4642 had information recorded
on their gangrene status: 81.6% (n=3787) were categorised as
‘never gangrene’, 18.4% (n=855) as ‘ever gangrene’ and 5.6%
(n=258) as ‘current gangrene’. The three groups were generally
similar regarding demographics and SSc characteristics, although
Table 1 Enrolment characteristics and patient demographics according to gangrene status*
Never† gangrene
(n=3787)
Ever‡ gangrene
(n=855)
Current gangrene
(n=258)§
Gender
Female, % 82.1 77.7 77.5
Age at enrolment
Mean (95% CI), years 54.4 (53.9 to 54.8) 54.8 (53.9 to 55.8) 52.8 (50.9 to 54.7)
Smoking status
n 3386 757 233
Current, % 14.4 17.6 24.0
Former, % 23.3 25.6 17.6
Never, % 62.3 56.8 58.4
Pack-years of smoking
n 868 206 73
Mean (95% CI) 37.8 (31.3 to 44.3) 37.9 (27.5 to 48.4) 44.9 (24.9 to 64.9)
Age at first RP
n 3409 752 229
Mean (95% CI), years 41.3 (40.8 to 41.8) 40.7 (39.6 to 41.8) 41.2 (39.0 to 43.3)
Age at first DU
n 3000 700 218
Mean (95% CI), years 47.6 (47.1 to 48.2) 47.1 (45.9 to 48.2) 48.3 (46.1 to 50.5)
SSc cutaneous subset
n 3774 850 256
Diffuse SSc, % 37.7 32.0 33.6
Limited SSc, % 52.3 58.2 54.3
Overlap, % 6.5 6.0 7.8
Other, % 3.6 3.8 4.3
Organ manifestations
n 3787 855 258
GI tract, % 54.0 56.8 46.5
Lung fibrosis, % 40.4 40.1 38.0
PAH, % 12.1 15.2 13.2
Heart, % 9.9 10.9 12.4
Kidney, % 4.1 6.0 5.8
Time from first RP to enrolment visit
n 3409 752 229
Mean (95% CI), years 13.1 (12.8 to 13.5) 14.4 (13.6 to 15.3) 11.9 (10.4 to 13.5)
Time from first DU to enrolment visit
n 3000 700 218
Mean (95% CI), years 5.9 (5.7 to 6.2) 7.4 (6.8 to 8.0) 4.6 (3.8 to 5.5)
Continued
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more current smokers at enrolment were in the ‘ever gangrene’
and ‘current gangrene’ groups than in the ‘never gangrene’
group, and the ‘current gangrene’ group had the shortest time
between ﬁrst RP and enrolment (table 1). The proportion of
patients with a history of DU-associated complications, interven-
tions and hospitalisations was greater in the ‘ever gangrene’
group compared with the ‘never gangrene’ group.
Overall, 3809 patients were eligible for inclusion in the ULR
analysis; the ﬁnal number of patients included in each ULR
model varied depending on missing data (table 2A). On MLR
analysis, being a current/former smoker, having ≥3 ﬁnger DUs,
previous gangrene and previous upper limb sympathectomy
were independent risk factors at enrolment for development of
incident gangrene (table 2B).
This analysis was the largest to date describing an SSc–DU
population according to the presence/history of gangrene at
enrolment and risk factors for incident gangrene during
follow-up. It has demonstrated that, in current practice, gangrene
Table 1 Continued
Never† gangrene
(n=3787)
Ever‡ gangrene
(n=855)
Current gangrene
(n=258)§
Antibodies, n1/n2 (%)
ACA 1184/2942 (40.2) 303/668 (45.4) 88/216 (40.7)
ANA 3307/3511 (94.2) 750/785 (95.5) 226/238 (95.0)
Anti-Scl 70 1397/3145 (44.4) 282/690 (40.9) 87/218 (39.9)
Anti-U1 RNP 170/2158 (7.9) 52/470 (11.1) 17/151 (11.3)
Anti-U3 RNP 59/1534 (3.8) 19/300 (6.3) 4/104 (3.8)
RNA polymerase III 127/1584 (8.0) 25/323 (7.7) 6/103 (5.8)
Employed/self-employed, n (%) 983/2674 (36.8) 167/564 (29.6) 75/207 (36.2)
History of complications/interventions, % (95% CI)¶
Critical digital ischaemia 30.1 (28.5 to 31.8) 82.2 (78.6 to 85.4) 69.4 (61.6 to 76.4)
Gangrene – 91.7 (89.7 to 93.5) 71.9 (65.9 to 77.4)
Autoamputation 3.1 (2.6 to 3.7) 24.1 (21.2 to 27.2) 15.9 (11.6 to 21.1)
Soft-tissue infection requiring systemic antibiotics 23.9 (22.5 to 25.3) 53.5 (49.9 to 57.0) 44.5 (38.1 to 51.1)
Osteomyelitis 1.3 (0.9 to 1.7) 11.9 (9.7 to 14.3) 7.4 (4.4 to 11.4)
Hospitalisations for DUs 32.7 (31.2 to 34.2) 70.1 (66.9 to 73.2) 58.9 (52.5 to 65.2)
Upper limb sympathectomy 2.2 (1.8 to 2.7) 8.8 (6.9 to 10.9) 7.2 (4.2 to 11.2)
Digital sympathectomy 1.4 (1.0 to 1.8) 4.8 (3.4 to 6.5) 3.4 (1.5 to 6.6)
Arterial reconstruction 0.7 (0.5 to 1.0) 2.1 (1.3 to 3.4) 4.3 (2.1 to 7.7)
Arthrodesis 1.4 (1.0 to 1.9) 5.7 (4.1 to 7.6) 2.0 (0.5 to 4.9)
Debridement 7.5 (6.6 to 8.4) 25.7 (22.5 to 29.1) 21.0 (15.6 to 27.2)
Surgical amputation 2.4 (1.9 to 3.0) 34.0 (30.5 to 37.5) 18.9 (13.8 to 24.8)
Use of parenteral prostanoids 51.6 (49.9 to 53.2) 74.4 (71.2 to 77.4) 74.4 (68.3 to 79.8)
Prior DUs, n1/n2 (%) 3759/3787 (99.3) 852/855 (99.6) 255/258 (98.8)
Ongoing medications, %
n 3787 855 258
Analgesics and anti-inflammatories 52.4 60.6 65.1
Immunosuppressants 33.5 28.2 29.5
Systemic antibiotics 13.3 19.6 36.0
ERAs 39.9 52.0 50.4
CCBs 46.0 52.5 53.1
Prostacyclins 35.0 36.5 51.9
PDE-5i 5.9 7.6 5.8
Topical DU treatments 19.1 24.4 36.8
Other medications 64.8 74.2 67.1
ERA+PDE-5i 2.2 3.3 2.7
ERA+prostacyclin 14.3 18.5 24.4
PDE-5i+prostacyclin 1.7 2.8 3.1
ERA+PDE-5i+prostacyclin 0.8 1.5 1.6
ERA only** 24.1 31.8 24.8
*Only patients who provided information on gangrene status (n=4642/4944) were categorised.
†Patients with no past and no current gangrene.
‡Patients with past and/or current gangrene.
§Patients with current gangrene at enrolment. The current gangrene group is a subset of the ‘ever gangrene’ group.
¶Data include only patients who provided information on the given item.
**Out of ERA, PDE-5i and prostacyclins, only ERA is ticked.
ACA, anticentromere antibody; ANA, antinuclear antibody; CCB, calcium channel blocker; DU, digital ulcer; ERA, endothelin receptor antagonist; GI, gastrointestinal; n1/n2, n patients
tested positive/n patients who had the test done; PAH, pulmonary arterial hypertension; PDE-5i, phosphodiesterase-type 5 inhibitor; RNP, ribonucleic protein; RP, Raynaud’s phenomenon;
SSc, systemic sclerosis.
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is still a common event occurring in 18% of patients with SSc–
DUs. Participating centres involved in the DUO Registry are spe-
cialist centres for the management of SSc–DUs; this may be
selective for patients with more severe vascular disease, and
therefore more prevalent gangrene. Multivariate analyses indi-
cated that, in patients with no current gangrene, along with pre-
vious gangrene, being a current/former smoker, having ≥3 DUs
and previous upper limb sympathectomy were independent risk
factors at enrolment for developing incident gangrene. These
results will help to risk-stratify patients with SSc–DUs and to
evaluate preventive gangrene management strategies.
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Table 2 Risk factors associated with the development of incident gangrene during the observation period
Risk factor Incident gangrene n/N (%) No incident gangrene, n/N (%) OR (95% CI) p Value*
(A) ULR (N=3809)† N=243 N=3566
Female gender 189/243 (77.8) 2938/3566 (82.4) 0.73 (0.53 to 1.01) 0.055
Smoking status
Current 45/205 (22.0) 438/3102 (14.1) 1.91 (1.32 to 2.76) <0.001
Former 58/205 (28.3) 728/3102 (23.5) 1.46 (1.04 to 2.04) 0.028
Number of finger DUs at enrolment
1–2 89/236 (37.7) 1315/3546 (37.1) 1.27 (0.93 to 1.72) 0.132
3+ 58/236 (24.6) 666/3546 (18.8) 1.54 (1.09 to 2.17) 0.015
Anti-Scl 70 103/196 (52.6) 1279/2872 (44.5) 1.39 (1.04 to 1.87) 0.027
Previous gangrene 96/229 (41.9) 404/3378 (12.0) 4.75 (3.57 to 6.34) <0.0001
Previous autoamputation 32/231 (13.9) 188/3386 (5.6) 2.69 (1.78 to 4.04) <0.0001
Previous soft-tissue infection requiring systemic antibiotics 94/222 (42.3) 933/3253 (28.7) 1.76 (1.33 to 2.32) <0.0001
Previous osteomyelitis 19/232 (8.2) 84/3367 (2.5) 3.24 (1.19 to 5.47) <0.0001
Ongoing autoamputation 6/242 (2.5) 46/3552 (1.3) 2.32 (0.97 to 5.57) 0.059
Ongoing osteomyelitis 4/243 (1.6) 24/3558 (0.7) 2.36 (0.80 to 6.99) 0.121
Previous hospitalisation(s) for DUs (at least 1 day) 144/231 (62.3) 1290/3385 (38.1) 2.49 (1.89 to 3.29) <0.0001
Previous upper limb sympathectomy 20/228 (8.8) 100/3345 (3.0) 3.24 (1.94 to 5.40) <0.0001
Previous digital sympathectomy 11/228 (4.8) 58/3341 (1.7) 2.70 (1.38 to 5.31) 0.004
Previous arterial reconstruction 5/227 (2.2) 21/3336 (0.6) 3.43 (1.25 to 9.44) 0.017
Not employed/self-employed 205/243 (84.4) 2687/3566 (75.4) 1.78 (1.22 to 2.61) 0.003
(B) MLR‡ (N=2479) N=157 N=2322
Observation time, mean (SD), weeks 174.7 (78.7) 126.2 (78.9) 1.03 (1.02 to 1.04) <0.0001
Smoking status
Current 27/157 (17.2) 311/2322 (13.4) 1.72 (1.07 to 2.77) 0.025
Former 47/157 (29.9) 509/2322 (21.9) 1.69 (1.14 to 2.51) 0.009
Number of finger DUs at enrolment
1–2 60/157 (38.2) 951/2322 (41.0) 1.35 (0.90 to 2.03) 0.144
3+ 46/157 (29.3) 491/2322 (21.1) 1.69 (1.09 to 2.62) 0.020
Anti-Scl 70 79/157 (50.3) 1031/2322 (44.4) 1.39 (0.99 to 1.96) 0.058
Previous gangrene 63/157 (40.1) 244/2322 (10.5) 4.67 (3.24 to 6.73) <0.0001
Previous upper limb sympathectomy 15/157 (9.6) 67/2322 (2.9) 2.21 (1.15 to 4.27) 0.018
*Wald χ2 test.
†For the ULR analysis, observation time was a fixed covariate in the model. Data are shown for variables having p<0.15 and n>3000 for the patients for whom information is available).
‡For the MLR analysis, observation time was forced into the model as a fixed covariate and not included by the forward selection procedure; variables were selected with a selection
criterion of p=0.15. Data are shown for the subset of patients making up the final models (n=2479) to allow comparison with the full cohort.
ACA, anticentromere antibody; ANA, antinuclear antibody; DU, digital ulcer; MLR, multivariable logistic regression; PAH, pulmonary arterial hypertension; RNP, ribonucleic protein;
ULR, univariable logistic regression.
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